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Abstract 
PPARγ is a pharmacological target in inflammatory and metabolic diseases. Upon agonistic treatment or 
following antagonism, binding of co-factors is altered, which consequently affects PPARγ-dependent 
transactivation as well as its DNA-independent properties. Therefore, establishing techniques to 
characterize these interactions is an important issue in living cells.  
Methods: Using the FRET pair Clover/mRuby2, we set up a flow cytometry-based FRET assay by 
analyzing PPARγ1 binding to its heterodimerization partner RXRα. Analyses of PPARγ-reporter and 
co-localization studies by laser-scanning microscopy validated this system. Refining the system, we 
created a new readout to distinguish strong from weak interactions, focusing on PPARγ-binding to the 
co-repressor N-CoR2. 
Results: We observed high FRET in cells expressing Clover-PPARγ1 and mRuby2-RXRα, but no FRET 
when cells express a mRuby2-RXRα deletion mutant, lacking the PPARγ interaction domain. Focusing on 
the co-repressor N-CoR2, we identified in HEK293T cells the new splice variant N-CoR2-ΔID1-exon. 
Overexpressing this isoform tagged with mRuby2, revealed no binding to Clover-PPARγ1, nor in murine 
J774A.1 macrophages. In HEK293T cells, binding was even lower in comparison to N-CoR2 constructs in 
which domains established to mediate interaction with PPARγ binding are deleted. These data suggest a 
possible role of N-CoR2-ΔID1-exon as a dominant negative variant. Because binding to N-CoR2-mRuby2 
was not altered following activation or antagonism of Clover-PPARγ1, we determined the effect of 
pharmacological treatment on FRET intensity. Therefore, we calculated flow cytometry-based FRET 
efficiencies based on our flow cytometry data. As with PPARγ antagonism, PPARγ agonist treatment did 
not prevent binding of N-CoR2.  
Conclusion: Our system allows the close determination of protein-protein interactions with a special 
focus on binding intensity, allowing this system to characterize the role of protein domains as well as the 
effect of pharmacological agents on protein-protein interactions. 
Key words: binding affinity and intensity, co-localization analysis, flow cytometry-based FRET assay, FRET, 
N-CoR2, NHR co-factors protein-protein interactions, PPARγ1, RXRα 
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Introduction 
Förster´s resonance energy transfer (FRET) 
between fluorescent proteins is an elegant 
non-invasive technique available to detect direct 
protein-protein interactions in living cells. It is based 
upon the energy transfer from an excited donor 
fluorophore to an adjacent acceptor fluorophore, 
resulting in decreased fluorescence emission by the 
donor and enhanced fluorescence emission by the 
acceptor [1–3]. For direct protein-protein interactions, 
FRET is highly dependent on the distance between the 
two fluorophores. Accordingly, this phenomenon 
only occurs when the distance between donor and 
acceptor ranges between 1-10 nm and the emission 
spectra of the donor overlaps with the excitation 
spectra of the acceptor [4]. In addition, FRET is also 
dependent on the geometry of the fluorophores in a 
donor-acceptor FRET pair. 
A large number of FRET methods, such as 
fluorescence lifetime imaging microscopy (FLIM), 
time-correlated single photon counting (TCSPC) or 
time-resolved (TR) energy transfer by TR-FRET, have 
been developed to measure fluorescence lifetime over 
the last few years. However, major limitations still 
exist [5–7]. Mostly, FRET measurements are done by 
complex fluorescence microscopy or analysis, which 
allows only the analysis of a small number of cells and 
essentially precludes high-throughput-screening 
(HTS) for protein interactions. 
A new innovative method to overcome these 
limitations is to detect and quantify FRET by flow 
cytometry [8, 9]. This non-invasive, sensitive and 
quantitative method allows the study of direct 
protein-protein interactions in large numbers of living 
cells and samples in a reasonable amount of time. 
Another new FRET-based method is related to the 
assessment of the binding affinity based on the 
determination of the FRET intensity via the 
measurement of the median fluorescence intensities 
(MFI) value to calculate the flow cytometry-based 
FRET efficiencies to rate the binding strength and 
thus, it allows to detect changes in the affinity and 
intensity of protein-protein interactions [10–13].  
Cyan and yellow fluorescent proteins (CFPs and 
YFPs) are generally used as FRET fluorophores. 
However, photophysical aspects of CFPs and YFPs, 
like rapid multi-rate and reversible photobleaching 
are problematic for FRET [14]. Consequently, many 
CFP- and YFP-based FRET reporters produce only 
small changes in FRET. Alternative FRET pairings 
between a green fluorescent protein (GFP) or YFP and 
an orange or red fluorescent protein (OFP or RFP) 
have been explored, but still have major limitations, 
i.e. low signal-to-noise ratio. Consequently, FRET 
efficiency and shifts in terms of fluorescence intensity 
upon FRET are too small to measure subtle 
differences in alterations of protein binding, for 
instance disturbance of interaction by drugs. A 
systematically developed, new FRET pair to overcome 
and minimize these limitations is based on 
Clover/mRuby2, one of the brightest GFP-based, 
respectively, brightest RFP-based fluorescence probes 
characterized so far, with properties better suited to a 
wide range of FRET applications [14]. 
In recent years, a few new drug screening 
systems have been developed to determine the 
molecular, pharmacological and toxicological 
potential of new and existing drugs and to identify 
and characterize drug-induced protein-protein 
interactions in detail. Preclinical in vitro screening 
systems are essential for the development and 
discovery of new drugs but major limitations, such as 
high costs, low throughput, and limitations with 
respect to specificity and sensitivity, still exist. For this 
reason, new innovative screening systems are crucial 
to be able to identify new therapeutic drugs, their 
potential combinations with existing drugs and 
drug-induced protein-protein interactions.  
In view of the crucial role of human peroxisome 
proliferator-activated receptor gamma (PPARγ) in the 
development of several obesity-related cancers and as 
a potential therapeutic target for autoimmune and 
inflammatory diseases [15–17], we developed an 
improved Clover/mRuby2-based flow cytometry- 
based FRET assay which proved to be suitable for 
determination of both protein-protein interactions 
and alterations in protein binding intensity and 
affinity upon drug treatment of living cells.  
The ligand-dependent activated transcription 
factor, PPARγ belongs to the nuclear hormone 
receptor (NHR) superfamily and plays a crucial role 
in the development of several human diseases and as 
a therapeutic target [15–18]. It is subdivided into four 
isoforms [19, 20]. PPARγ1 is expressed in nearly all 
tissues, including heart, muscle, colon, kidney, 
pancreas, and spleen [21–25], whereas PPARγ2 is 
mainly expressed in adipose tissues [26–28]. The 
PPARγ isoform 3 was identified in macrophages, 
large intestine, and white adipose tissues and isoform 
4 in endothelial cells [19, 20]. PPARγ possesses a 
central deoxyribonucleic acid (DNA)-binding domain 
that recognizes sequence-specific PPAR response 
elements (PPREs) in the promoter region of target 
genes [26, 29]. After activation by a tissue- and natural 
or synthetic ligand-specific stimulus, PPARγ is 
translocated to the nucleus, where it changes its 
structure and regulates gene transcription which is 
important for cell differentiation, various metabolic, 
physiological and pathophysiological processes 
[30–34].  
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The PPARγ-regulated transcriptional activation 
of target genes is a complex multistep process and 
depends on the binding or not of a cognate ligand to 
the receptor. The process is achieved by 
heterodimerization of PPARγ with RXRα, binding to 
PPREs and finally the recruitment of co-factors and 
other nuclear co-regulatory proteins [35–39]. PPARγ 
acts as a ligand-dependent regulator of transcription 
and this depends on its ability to interact with 
co-regulator proteins but it can also act in an unbound 
manner [40]. PPARγ can also bind directly to other 
proteins and inhibits signal transduction. This 
capability, called transrepression, is mainly mediated 
by direct protein-protein interactions between PPARγ 
and other transcription factors [41–43]. In this way, 
PPARγ inhibits pro-inflammatory signalling and 
induces an anti-inflammatory response [44, 45]. 
Typically, activation of the PPARγ-RXRα heterodimer 
by a PPARγ agonist triggers conformational changes 
in the receptor which releases the co-repressor 
complex and PPARγ recruits co-factor complexes or 
co-activators, such as steroid receptor co-activator 1 
(SRC1), SRC3 and cyclic adenosine monophosphate 
response element binding protein (CBP)/p300 to the 
promoter region of target genes to initiate 
transcription [46–48]. These, in turn, assemble a 
multi-component complex that stimulates 
transcription both through direct interaction with the 
core transcription machinery and through the 
acetylation of histone tails that make the adjacent 
chromatin transcriptionally competent. Subsequently, 
co-repressors are recruited to the DNA-bound PPARγ 
to nucleate the assembly of the repressor complex. 
An important PPARγ co-repressor is N-CoR2, 
which plays a crucial role in adipocyte differentiation 
and regulation of adipogenesis, insulin sensitivity and 
type 2 diabetes mellitus [49, 50]. N-CoR2 consists of 
N-terminal repressor domains (RDs) that can 
associate with histone deacetylases and SWI3 - 
adenosine deaminase 2 (ADA2) - N-CoR2 - 
transcription factor IIIB (TFIIIB) (SANT) domains that 
target the histone deacetylases, as well as two 
C-terminal interaction domains (IDs, ID1, ID2 and 
depending on the cell type there could be an 
additional ID3) that contain co-repressor nuclear 
receptor (CoRNR) box (NHR box) motifs [51–53]. 
Sequences within and outside these motifs mediate 
the interaction between co-repressors and many 
NHRs, including PPARγ, in which NHRs 
preferentially interact with the different IDs [54, 55]. 
Therefore, alternative splicing of single IDs 
themselves or between them is a crucial source of 
variability when functioning as interaction partner. 
N-CoR2 is recruited by PPARγ in the absence of an 
agonist or the presence of an antagonist of PPARγ and 
represses target gene expression by recruiting a 
histone deacetylase complex until an agonist triggers 
its disassembly accompanied by recruitment of 
co-activators [56–61]. The binding of the agonist to 
PPARγ results in a conformational change in the 
receptor, leading to loss of co-repressor binding and 
subsequent recruitment of co-activators. PPARγ can 
interact with N-CoR2 in solution, but in some contexts 
it is only a weak repressor, perhaps because the 
co-repressor binding affinity of PPARγ is weaker than 
other NHRs and is modulated by DNA binding [57, 
62–67].  
In this report, a systematically improved flow 
cytometry-based FRET assay for the molecular 
verification of specific protein-protein interactions of 
NHR (PPARγ isoform 1 hereinafter referred as 
PPARγ1) and co-factors (RXRα and N-CoR2) in living 
cells is described which combines, for the first time, 
the identification and characterization of binding 
intensity and affinity. Thus, by improving sensitivity, 
this assay system can be used for the identification of 
novel therapeutic targets for treatment of human 
diseases and for the detailed characterization of the 
binding profile of drugs. 
Methods 
Chemicals and reagents 
All chemicals and reagents were of the highest 
grade of purity and when not indicated otherwise, 
commercially available from AppliChem GmbH 
(Darmstadt, Germany), Carl Roth GmbH (Karlsruhe, 
Germany), Merck KGaA (Darmstadt, Germany) and 
Sigma-Aldrich Chemie GmbH (Schnelldorf, 
Germany). The PPARγ antagonist, GW9662 [68], was 
acquired from Cayman Chemical Company (Ann 
Arbor, USA) and the PPARγ agonist, rosiglitazone, 
from Enzo Life Sciences GmbH (Lörrach, Germany). 
Cell culture medium and supplements were 
purchased from PAA Laboratories GmbH (Cölbe, 
Germany) and Sigma-Aldrich Chemie GmbH. 
Cell culture 
Human HEK293T cells [69] and murine J774A.1 
macrophages (ATCC® TIB-67TM) [70] were obtained 
from LGC Standards GmbH (Wesel, Germany). 
HEK293T cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) and J774A.1 cells in Roswell 
Park Memorial Institute (RPMI)-1640 in a humidified 
5% carbon dioxide (CO2) atmosphere at 37 °C. Cell 
culture medium contained 10% (v/v) heat-inactivated 
fetal calf serum (FCS), 100 units/ml penicillin and 
100 µg/ml streptomycin. The medium was changed 
three times a week and cells passaged before reaching 
confluency. When using dimethyl sulfoxide (DMSO), 
in all cases, the final concentration of DMSO did not 
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exceed 0.1%, a concentration that was not cytotoxic to 
the cells. 
Generation and cloning of expression vectors 
Constructs were generated by inserting the 
coding sequences of Clover, mRuby2, Clover- 
PPARγ1, mRuby2-RXRα and N-CoR2-mRuby2 into 
pHR´SIN-cPPT-SE by replacing the EGFP of the 
vector. Therefore, the coding regions of Clover, 
mRuby2 and by a 63bp-linker fused Clover-mRuby 
were amplified by polymerase chain reaction (PCR) 
from pcDNA3-Clover (Addgene#40259), pcDNA3- 
mRuby2 (Addgene#40260) and pcDNA3.1-Clover- 
mRuby2 (Addgene#49089) elongated with the 
additional bases of 5´-CGCCCGGGGGGGATCGCC 
GCCACC-3´ on their 5´ end and 5´-CCTGCA 
GGCATGCAA-3´ on their 3´ end for subsequent 
recombination into the BamHI-SbfI linearized target 
vector by In-Fusion® HD cloning (Clontech 
Laboratories, Inc., Mountain View, USA). Fusion 
constructs of Clover-PPARγ1, mRuby2-RXRα and 
N-CoR2-mRuby2 were generated by multiple 
fragment cloning via the same approach. The single 
genes were amplified, whereas both primers for the 
amplification of the fluorophore had an additional 
base overhang, one a homologue of the vector and one 
of its fusion partner genes. In contrast, only one 
primer for the amplification of the transcription 
factors/repressor had an overhang for the 
recombination directly with the vector. Thus, 
pDsRed-Monomer-C1-PPARγ1 [71] and 
pEGFP-C1-RXRα [72] were used as template DNA for 
full length human PPARγ1 and human RXRα, 
whereas a 5´-truncated human N-CoR2 was amplified 
from HEK293T cell cDNA (GenBank accession 
number MH507335.1), which contains only the ID2 
and not the ID1 exon (ID2/∆ID1 exon), using 5´- 
ATGAGCGTCCTCGAGAGGCAAA-3´ as 5´-primer. 
The coding sequences of the single genes were fused 
together by In-Fusion® HD cloning, additionally 
amplified as one gene fragment and then inserted into 
the target vector. 
Since HEK293T do not have the complete exon 
containing the ID1 box motif, the whole ID1 exon of 
the sequence 5´-GCCTTATGACCTATAGAAGCCAG 
GCGGTGCAGGAACATGCCAGCACCAACATGGG
GCTGGAGGCCATAATTAGAAAGGCACTCATGG-
3´ was synthesized by IDT – Integrated DNA 
technologies, Inc. (Coralville, USA), amplified and 
fused into the vector construct of N-CoR2 ID2/∆ID1 
exon-mRuby2 to generate N-CoR2-mRuby2. For the 
generation of the different N-CoR2 mutants, ∆CoRNR 
box ID2 and ∆CoRNR box ID1 the appropriate DNA 
sequences 5´-CTGGCCCAGCACATCAGTGAGGTC 
ATC-3´ (for CoRNR box ID2) and 5´-CTGGAG 
GCCATAATTAGAAAGGCACTC-3´ (for CoRNR box 
ID1) were deleted out of the N-CoR2 sequence by site 
directed mutagenesis. The same approach was used 
for the generation of mRuby2-RXRα Δ414-462. 
Genbank accession numbers are: Clover (JX489388); 
mRuby2 (JX489389); human PPARγ1 (NP_005028.4); 
human RXRα (NP_002948.1), N-terminal truncated 
human N-CoR2∆1-1105; 2310-2338 (NP_001070729.2). 
Transfection, lentiviral transduction and cell 
sorting 
To generate infectious lentiviral particles for 
transduction of expression vectors, 2 × 106 
HEK293T cells were seeded into 10 cm dishes and 
cultured overnight, as described above, to allow 
attachment of HEK293T cells. The next day, HEK293T 
cells were transfected using the JetPRIMETM 
transfection reagent (PEQLAB Biotechnologie GmbH, 
Erlangen, Germany), as described by the 
manufacturer. Transfection was carried out with 
1.5 µg of the second-generation lentiviral packaging 
plasmid psPAX2 (Addgene#12260), 0.5 µg of the 
envelope expressing plasmid pMD2.G 
(Addgene#12259) and 2 µg of the cloned expression 
vector, encoding for the gene of interest. After 4 h, 
transfection medium was replaced and HEK293T cells 
were cultured in fresh growth medium for another 
24 h to 48 h. Gene activity was analyzed by 
fluorescence microscopy. Twenty-four to 48 h post 
transfection the supernatant containing infectious 
lentiviral particles was harvested, centrifuged 
(500 x g, 4 °C, 5 min) and filtered through a 0.2 μm 
filter (Merck KGaA). The Lenti-XTM Concentrator 
reagent (Takara Bio Europe SAS, Saint-Germain- 
en-Laye, France) was used as described by the 
manufacturer for concentrating lentiviral stocks. For 
transduction, 1 x 105 of target HEK293T or J774A.1 
cells were incubated in 6 well plates for 24 h to 48 h in 
cell culture medium containing concentrated 
infectious lentiviral particles. Subsequently, the 
medium was changed daily for at least ten days. 
Afterwards HEK293T cells were sorted for green- 
and/or red-positive cells using the BD FACSAria™ III 
cell sorter (BD Biosciences, Heidelberg, Germany) and 
the FACS Diva software (BD Biosciences, Heidelberg, 
Germany). 
PPARγ-dependent transactivation assay of 
HEK293T cells 
For the PPARγ-dependent transactivation assay, 
1 × 104 HEK293T cells per well were seeded into 
96-well plates and cultured overnight, as described 
above, to allow attachment of the HEK293T cells. The 
next day, the HEK293T cells were transiently 
transfected using the JetPRIMETM transfection reagent 
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(PEQLAB Biotechnologie GmbH), as described by the 
manufacturer. Transfection was carried out with 
0.01 µg of the cloned expression vector(s), encoding 
the gene(s) of interest, 0.09 µg per well p(AOX)3- 
TK-Luc (89, 90) and 0.0005 µg per well pRL-CMV 
(Promega GmbH, Mannheim, Germany). After 4 h, 
the transfection medium was replaced and the 
HEK293T cells were cultured in fresh growth medium 
for another 24 h.  
The PPARγ-dependent transactivation assay was 
based on the PPRE containing reporter vector 
p(AOX)3-TK-Luc. The cloned expression vector(s), 
encoding for the gene(s) of interest were 
co-transfected, as described above, in combination 
with the control vector pRL-CMV, encoding Renilla 
luciferase, to normalize Firefly luciferase activity for 
transfection efficiency. Following transfection, the 
cells were incubated with 1 µM rosiglitazone and 
10 μM GW9662 for 24 h alone or both in combination. 
The PPARγ-dependent transactivation assay in 
HEK293T cells, using a 96-well plate format, was 
performed in quadruple. Transactivation was 
analyzed using a 96-well plate format in a Mithras 
LB940 multimode reader (Berthold Technologies, Bad 
Wildbad, Germany) or an EnSpire® Multimode Plate 
Reader (Perkin Elmer, Inc., Waltham, USA). 
Western blot analysis 
HEK293T cells were resuspended in lysis buffer 
and sonicated. After centrifugation (15,000 x g, 4 °C, 
5 min), the protein concentration was determined in 
the lysate by a Lowry protein assay kit (Bio-Rad 
Laboratories GmbH, Munich, Germany). For immune 
detection of Clover, mRuby2, Clover fused (63bp) 
mRuby2, Clover-PPARγ1, mRuby2-RXRα, mRuby2- 
RXRα Δ414-462 and N-CoR2-mRuby2 constructs, 
100 µg protein per sample was separated on 10% 
sodium dodecyl sulfate (SDS) polyacrylamide gels 
followed by transfer onto nitrocellulose membranes 
(both Bio-Rad Laboratories GmbH) basically 
following standard procedures. Subsequently, 
membranes were incubated with first antibodies 
against GFP (1:1,000; ab1218, Abcam plc, Cambridge, 
UK), human PPARγ (1:1,000; D69, Cell Signaling 
Technology, Danvers, USA), human RXRα (1:1,000; 
NB100-1466, Novus Biologicals, LLC, Littleton, USA), 
human N-CoR2 (1:1,000; ab2781, Abcam plc) and tRFP 
(1:1,000; AB233, Evrogen Joint Stock Company, 
Moscow, Russia) followed by Alexa Fluor® 488, 546 or 
647 (Life Technologies Inc., Carlsbad, USA) 
fluorescent dyes secondary antibodies (1:10,000). Blots 
were visualized using the ChemiDoc XRS+ system 
(Bio-Rad Laboratories GmbH). 
Fluorescence microscopy 
For fluorescence microscopy, 2 x 104 HEK293T 
cells per well were seeded on all-in-one 8 wells 
chamber slides. Cultivation continued for 24 h, as 
described above, to allow attachment of the HEK293T 
cells, followed by fixation of cells by incubation with 
Roti®-Histofix solution (Carl Roth GmbH) combined 
with concomitant counterstaining of cell nuclei with 
1 μg/ml Hoechst 33342 dissolved in DMEM in the 
dark at 37 °C for 15 min. Subsequently, cells were 
washed twice with DMEM. The cells were excited 
with a laser at λex = 405 nm, 488 nm and 561 nm. 
Clover, mRuby2 and Hoechst 33342 were determined 
on the chamber slides using a 40x immersion water 
objective with a Zeiss confocal laser scanning 
microscope (CLSM) 510 Meta (Carl Zeiss AG, Jena, 
Germany). Uniform laser conditions regarding master 
and digital gains, pinholes and laser intensities were 
used for fluorescence detection among the 
fluorophores alone and for fluorophores assigned to 
different cellular functional proteins. 
Quantification of subcellular co-localization 
Correlation analysis of subcellular 
co-localization was performed using the open source 
image processing program ImageJ with the plugin 
“JACoP” [72]. For this, areas of single whole cells or 
nuclei were framed in brightfield or Hoechst-stained 
images and the Pearson´s correlation coefficient (PCC) 
of these regions were calculated from the images, 
requiring the use of the 488 nm and 561 nm laser. The 
single R-values obtained were transformed into Fisher 
z-values, which converts correlations into interval 
scales values. From these data means, standard 
deviation (SD) and significances were calculated and 
further separately transformed back into R-values.  
Fluorescence lifetime imaging microscopy 
(FLIM) 
The fluorescence lifetime of the fluorescent 
proteins depends on their microenvironment. 
Intermolecular interactions will change the 
fluorescence lifetime. Thus, the FLIM method was 
used to observe the capacity of the proteins to 
generate a FRET signal inside the cells. The cell 
images were observed with a FluoViewTM FV1000 
CLSM microscope (Olympus Europa SE & Co. KG, 
Hamburg, Germany) with FLIM-extension 
(PicoQuant, Berlin, Germany). The cells were excited 
with a 1 ns pulse laser at λex = 440 nm for fluorescence 
lifetime measurements. 
HEK293T cells were seeded on glass coverslips 
24 h before measurement and were viewed directly on 
the coverslip using a 60x immersion oil objective. All 
images were obtained from living cells to prevent 
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changes in the protein structure or its 
microenvironment during the procedure of cell fixing. 
The result was taken as a standard reference for flow 
cytometry-based FRET analyses. 
Flow cytometry measurements 
Flow cytometry-based FRET measurements 
were performed using a FACSFortessa (BD 
Bioscience) equipped with standard 488 nm and 
561 nm lasers. To measure Clover and FRET, cells 
were excited with the standard 488 nm laser and 
fluorescence was detected in the green channel with a 
standard 525/50 nm filter, while the FRET signal was 
measured with a standard 610/20 nm filter in the 
channel. The mRuby2 cells were excited with the 
standard 561 nm laser, while emission was also 
detected with a standard 610/20 nm filter. For each 
sample, we analyzed a minimum of 10,000 Clover- 
and/or mRuby2-positive cells according to the gating 
strategy shown in Figure 1F. Analyses of flow 
cytometric data were performed using the FlowJo 
software (Version X). 
Flow cytometry-based FRET efficiency 
Following appropriate gating of 
Clover/mRuby2-double positive cells, flow 
cytometry-based FRET efficiencies were calculated 
based on fluorescence medians of Clover (488/525 
nm), FRET (488/610 nm), and mRuby2 (561/610 nm) 
using the FRET calculator protocol provided by 
Ujlaky-Nagy et al. [11] with reference to our FLIM 
control setting. Single-positive as well as fluorescence 
negative cells served as background controls. Gating 
strategies are depicted in Supplementary Figures 1, 4, 
6, 7, 8, and 9. 
Statistics 
All data are presented as means ± SD. Each 
experiment was performed at least three times. 
Statistical analysis was done either with one- or 
two-way-analysis of variance modified with 
Bonferroni’s multiple comparison test or unpaired 
and paired Student’s t-test, respectively. Differences 
were considered significant as: *P ≤ 0.05, **P ≤ 0.01 
and ***P ≤ 0.001. 
Results 
Detection of Clover, mRuby2 and Clover fused 
(63bp) mRuby2 protein expression 
To confirm that the fluorophore probes to be 
used in this study were actually expressed in the cells 
used, the protein expression of the fluorophores 
Clover, mRuby2 and Clover fused with a linker 
sequence to mRuby2 (Clover fused (63bp) mRuby2) in 
human embryonic kidney 293 T (HEK293T) cells was 
verified by Western blot analysis. Stained with an 
antibody against GFP, Clover was only detected in 
Clover-expressing HEK293T Clover, HEK293T Clover 
+ mRuby2 and HEK293T Clover fused (63bp) 
mRuby2 cells (Figure 1A). In turn, when stained with 
an antibody against tRFP, only in mRuby2-expressing 
HEK293T mRuby2, HEK293T Clover + mRuby2 and 
HEK293T Clover fused (63bp) mRuby2 cells mRuby2 
was observed (Figure 1B). Neither when stained with 
an antibody against GFP nor with an antibody against 
tRFP was the protein expression of Clover, mRuby2 or 
Clover fused (63bp) mRuby2 detected in wild type 
(WT) and Mock transfected HEK293T cells. 
Determination of the cellular localization of 
Clover, mRuby2 and Clover fused (63bp) 
mRuby2 by fluorescence microscopy 
To determine the cellular localization of the 
fluorophores used, corresponding Clover- and 
mRuby2-expressing HEK293T cells were mounted on 
all-in-one chamber slides and fixed. To distinguish 
between cytosolic and nuclear localization, Hoechst 
33342 was used as a nuclear counterstain. As shown 
in Figure 1C, mRuby2 (panel 2), Clover (panel 3) and 
Clover fused (63bp) mRuby2 were evenly distributed 
throughout the cell. 
Validation of Clover, mRuby2 and Clover fused 
(63bp) mRuby2 for flow cytometry FRET 
measurements by FLIM 
FLIM was used to determine the different 
fluorescence lifetimes of the intracellular fluorescent 
proteins. HEK293T cells were transduced to stably 
express Clover/mRuby2 alone or in combination and 
Clover fused (63bp) mRuby2 in order to investigate 
the potential FRET activity of the Clover fused (63bp) 
mRuby2 protein. As shown in Figure 1D and 1E, the 
fluorescence lifetime of Clover was highest with a 
frequency of 3.4 ns ± 0.1 ns, whereas the most 
frequent fluorescence lifetime of mRuby2 was 1.7 ns ± 
0.1 ns. In cells that expressed both Clover and 
mRuby2 as single proteins, only the fluorescence 
lifetime of Clover was detectable. In contrast, cells 
expressing Clover fused (63bp) mRuby2 showed a 
most frequent fluorescence lifetime of 2.7 ns ± 0.3 ns. 
This reduction in the fluorescence lifetime from 3.4 ns 
± 0.1 ns to 2.7 ns ± 0.3 ns resulted from changes in 
FRET activity. FRET efficiency of the fusion protein 
can be calculated from the lifetime of the construct 
and of the free Clover, roughly resulting in a value of 
0.23. This absolute measure of FRET is considered in 
calculating the flow cytometry-based FRET 
efficiencies. 
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Figure 1. Experimental setup and gating strategy of FRET measurements. Clover, mRuby2, Clover + mRuby2 and Clover fused (63bp) mRuby2 protein expression 
are shown in total HEK293T cell lysates by Western blot analysis against GFP (A) and tRFP (B). Fluorescence microscopy images (C) of Clover, mRuby2, Clover + mRuby2 and 
Clover fused (63bp) mRuby2 expressing HEK293T cells. Panel 1 (1) shows the brightfield. Cells expressing mRuby2 are depicted in panel 2 (2), Clover-positive cells in panel 3 (3). 
Cell nuclei were counterstained with Hoechst 33342 (panel 4 (4)). An overlay to estimate cytosolic and nuclear region is provided in panel 5 (5). FLIM images (D) of HEK293T 
cells with the controls Clover, mRuby2, Clover + mRuby2 and Clover fused (63bp) mRuby2. The histogram (E) shows the normalized frequency of fluorescence lifetimes in the 
images. Experimental setup and gating strategy to measure FRET by flow cytometry are depicted in living cells (F). HEK293T cells were stably transduced with the controls 
Clover, mRuby2, Clover + mRuby2 as well as the Clover fused (63bp) mRuby2 and analyzed using a flow cytometer. Double positive cells were gated in panel 1 (1). False-positive 
FRET signals resulting from mRuby2 excitation by the 488 nm laser were excluded in panel 2 (2). In panel 3 (3), the remaining cells were evaluated for FRET by adjusting a gate 
defining cells which were co-transduced with Clover + mRuby2 and should be FRET-negative. The numbers in panel 3 (3) give total percentages of FRET-positive HEK293T cells. 
Images and flow cytometry-plots are representative for experiments which were performed at least three times. (G) FRET efficiencies were determined as described in Materials 
and Methods by analyzing Clover/mRuby2-double positive cells only. Experiments were performed at least three times. ***P ≤ 0.001. 
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Establishment of Clover, mRuby2 and Clover 
fused (63bp) mRuby2 for FRET measurement 
by flow cytometry 
In a previous study, Banning and colleagues 
established a flow cytometry-based FRET assay 
system to identify and analyze protein-protein 
interactions in living cells [8]. For the analysis of 
interactions of PPARγ1 with its co-factor RXRα and its 
co-repressor N-CoR2 in living cells, we adapted and 
extended this innovative method. We established a 
cytometry-based FRET assay with the FRET pair 
fluorophores Clover/mRuby2 [14]. For FRET 
measurements by flow cytometry, we first analyzed 
HEK293T cells stably expressing Clover/mRuby2 
alone or in combination and Clover fused (63bp) 
mRuby2 (Figure 1F). We gated living cells to forward 
and side scatter (FSC/SSC, not shown) and 
compensated for Clover and mRuby2 to specifically 
evaluate FRET in double positive Clover + mRuby2 
and Clover fused (63bp) mRuby2 cells. A triangular 
gate was introduced in panel 2 and false-positive 
FRET signals resulting from mRuby2 excitation by the 
488 nm laser were excluded. A second triangular gate 
was introduced in panel 3, where FRET was plotted 
against Clover to determine FRET-positive cells. This 
gate was adjusted to FRET-negative HEK293T Clover 
+ mRuby2 cells. Consequently, HEK293T Clover and 
HEK293T mRuby2 cells exhibited no FRET signal, 
whereas 99.8% of cells expressing Clover fused (63bp) 
mRuby2 fusion protein (Figure 1F, panel 3) showed a 
FRET signal. These cells were further used as a 
positive control. In contrast, 0.0% cells expressing 
Clover and mRuby2 (Figure 1F, panel 3) as individual 
proteins showed FRET, thus representing the internal 
negative control. To verify our data, we analyzed the 
FRET efficiency. As shown in Supplementary Figure 
1, gating for Clover/mRuby-positive cells was 
performed. Fluorescence medians of Clover (488/525 
nm), FRET (488/610 nm), and mRuby2 (561/610 nm) 
were used to calculate FRET efficiency, including 
medians of fluorescence negative HEK293T cells as 
background control (Figure 1G), supporting the 
information from the raw flow cytometric data shown 
in Figure 1F.  
Verification of Clover-PPARγ1, mRuby2-RXRα 
and mRuby2-RXRα ∆414-462 protein 
expression 
Expression of Clover-PPARγ1 (Figure 2A), 
mRuby2-RXRα (Figure 2B) and mRuby2-RXRα 
∆414-462 (Figure 2C) fusion proteins in HEK293T cells 
was verified by Western blot analysis. Specific 
antibodies against GFP, tRFP, human PPARγ and 
human RXRα were used. As shown in Figure 2D and 
2E, the Clover-PPARγ1 fusion protein was detected in 
cells when stably expressing Clover-PPARγ1, Clover- 
PPARγ1 + mRuby2-RXRα and Clover-PPARγ1 + 
mRuby2-RXRα ∆414-462. In the literature it is well 
established that due to the deletion of the C-terminus 
of RXRα and the associated lack of the amino acid 
(AA) sequence 414 to AA 462, RXRα ∆414-462 
significantly reduces binding to PPARγ [68]. The 
protein molecular weight of this deletion construct 
was 5.7 kDa smaller than the complete mRuby2-RXRα 
fusion protein (Figure 2F and 2G). Both constructs 
were only detected in cells expressing mRuby2-RXRα, 
mRuby2-RXRα ∆414-462, Clover-PPARγ1 + mRuby2- 
RXRα and Clover-PPARγ1 + mRuby2-RXRα 
∆414-462. WT and Mock transfected HEK293T cells 
were used as negative controls for expression of 
Clover-PPARγ1 (Figure 2D and 2E), mRuby2-RXRα 
(Figure 2F and 2G) and mRuby2-RXRα ∆414-462 
(Figure 2F and 2G). Our analysis at the protein level 
by Western blot, depicted in Figure 2G, indicates that 
the anti-tRFP antibody also binds to Clover, allowing 
detection of a specific band at the level of 
Clover-PPARγ1. This band is very prominent in 
co-transduced HEK293T Clover-PPARγ1 + 
mRuby2-RXRα cells and thus, shows clearly the 
simultaneous protein expression of the two fusion 
proteins in these cells. Due to the deletion of 48 AA 
(Δ414-462) of the PPARγ1 ID of RXRα, 
Clover-PPARγ1 and mRuby2-RXRα Δ414-462 are 
approximately equal in size. For this reason, only one 
band is visible in co-transduced HEK293 
Clover-PPARγ1 + mRuby2-RXRα Δ414-462 cells. 
Mechanistic functionality of Clover, Clover- 
PPARγ1, mRuby2, mRuby2-RXRα and 
mRuby2-RXRα ∆414-462 
To examine whether PPARγ-dependent 
transactivation is altered, we performed a set of 
experiments using a PPRE-dependent reporter 
system. HEK293T cells expressing Clover, 
Clover-PPARγ1, mRuby2, mRuby2-RXRα and 
mRuby2-RXRα ∆414-462 were treated for 24 h with 
1 µM of the PPARγ agonist, rosiglitazone and 10 µM 
of the irreversible binding PPARγ antagonist, 
2-chloro-5-nitrobenzanilide (GW9662) [68] or a 
combination of both. Firefly and control Renilla 
luciferase luminescence values were determined in 
each sample. The ratios of Firefly to Renilla luciferase 
luminescence were used for normalization. 
In line with its published action, rosiglitazone 
alone showed significant agonistic effects and led to 
an approximately 2.5-fold PPARγ-transactivation 
after 24 h stimulation in Clover-PPARγ1 cells 
(Figure 3A). In HEK293T WT and Mock transfected 
cells as well as HEK293T cells expressing Clover 
 Theranostics 2019, Vol. 9, Issue 19 
 
 
http://www.thno.org 
5452 
and/or mRuby2, rosiglitazone and GW9662 alone or 
in combination showed no agonistic effects and led to 
an approximately 1.25-fold higher transactivation of 
PPARγ compared to DMSO control treatment 
(Supplementary Figure 2). 
There were no differences between Clover + 
mRuby2-RXRα and Clover + mRuby2-RXRα ∆414-462 
cells in response to rosiglitazone (Figure 3B). In this 
case, a roughly 1.4-fold higher transactivation of 
PPARγ compared to DMSO control treatment was 
detected. In contrast to this observation, in 
Clover-PPARγ1 + mRuby2-RXRα and Clover- 
PPARγ1 + mRuby2-RXRα ∆414-462 cells, a 
significantly increased 2.5-fold to 3.25-fold 
PPARγ-transactivation was observed. Altogether, 
these results indicate that the Clover-PPARγ1 fusion 
protein is functional and responsive to drug 
treatment. 
Assessment of the fluorescence and cellular 
localization of Clover-PPARγ1, mRuby2-RXRα 
and mRuby2-RXRα ∆414-462 by fluorescence 
microscopy 
Fluorescence microscopy was used to assess the 
cellular localization of Clover-PPARγ1, 
mRuby2-RXRα and mRuby2-RXRα ∆414-462 in 
HEK293T cells. Cell nuclei were visualized by 
Hoechst 33342-staining (Figure 3C, panel 4), 
confirming the mainly nuclear localization of 
Clover-PPARγ1 (Figure 3C, panels 3 and 5), 
mRuby2-RXRα (Figure 3C, panels 2 and 5) and 
mRuby2-RXRα ∆414-462 (Figure 3C, panels 2 and 5).  
The PCC was used to assess the correlation 
between the subcellular co-localization of 
Clover-PPARγ1 with mRuby2-RXRα or 
mRuby2-RXRα ∆414-462. As shown in Figure 3D, 
significant differences in the PCC of HEK293T 
Clover-PPARγ1 + mRuby2-RXRα (0.912 ± 0.154) 
compared to HEK293T Clover-PPARγ1 + 
mRuby2-RXRα ∆414-462 (0.706 ± 0.226) were 
detected. Because of the overlapping spectra of the 
fluorophores Clover and mRuby2, a possible 
irradiation of fluorescence into each of the confocal 
microscopy channels was expected. Therefore, the 
PCC of cells expressing only single fusion proteins 
was also calculated. The highest background value 
was measured for Clover-PPARγ1 alone and was in 
the range of 0.7 (Supplementary Figure 3). 
Considering this value as background signal, 
mRuby2-RXRα ∆414-462 does not associate with 
Clover-PPARγ1, whereas the full-length RXRα seems 
to specifically co-localize (Figure 3D). 
 
 
Figure 2. Determination of Clover-PPARγ1, mRuby2-RXRα and mRuby2-RXRα ∆414-462 protein expression. Graphical scheme of the structure of the full 
length human PPARγ1 protein (A); the full length human RXRα protein (B) and the human RXRα deletion construct with a C-terminal absence of the sequence AA 414-462 (C). 
PPARγ1 was N-terminally labeled with the green fluorophore Clover and both of the two RXRα constructs N-terminally with the red fluorophore mRuby2. Clover-PPARγ1, 
mRuby2-RXRα and mRuby2-RXRα ∆414-462 protein expressions are shown in total HEK293T cell lysates visualized by Western blot analysis against human PPARγ (D), GFP 
(E), human RXRα (F) and tRFP (G). Images are representative of experiments which were performed at least three times. 
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Figure 3. Analysis of protein-protein interactions between Clover-PPARγ1, mRuby2-RXRα and mRuby2-RXRα ∆414-462. A PPARγ-dependent transactivation 
assay was used in HEK293T cells to verify the mechanistic functionality of the Clover, Clover-PPARγ1, mRuby2, mRuby2-RXRα and mRuby2-RXRα ∆414-462 (A and B). 
HEK293T cells expressing protein(s) as indicated were stimulated for 24 h with 1 µM rosiglitazone and 10 µM GW9662 alone or in combination. Values from PPARγ-dependent 
transactivation experiments are means ± SD of three to ten individual experiments. Each PPARγ-dependent transactivation assay experiment was performed in quadruple. *P ≤ 
0.05, **P ≤ 0.01 and ***P ≤ 0.001. Fluorescence microscopy images of HEK293T cells expressing Clover-PPARγ1, mRuby2-RXRα, mRuby2-RXRα ∆414-462, Clover-PPARγ1 + 
mRuby2-RXRα and Clover-PPARγ1 + mRuby2-RXRα ∆414-462 are depicted (C). The brightfield is shown in panel 1 (1). The mRuby2-positive cells are depicted in panel 2 (2), 
Clover in panel 3 (3), Hoechst 33342-stained cell nuclei in panel 4 (4) and an overlay to estimate the localization is provided in panel 5 (5). Images are representative for 
experiments which were performed at least three times. The PCC was used for the correlation quantification of the subcellular co-localization of Clover-PPARγ1 expressed in 
combination with mRuby2-RXRα or mRuby2-RXRα ∆414-462 (D). R-Values are means ± SD of at least 18 individual cells. ***P ≤ 0.001. Representative primary flow 
cytometry-plots from an experiment which was performed three times showing the amount of FRET-positive living HEK293T cells expressing Clover-PPARγ1 + mRuby2-RXRα 
and Clover-PPARγ1 + mRuby2-RXRα ∆414-462 (E). The numbers in panel 3 (3) give total percentages of HEK293T cells within the FRET gate. A comparison of the 
total percentages of FRET-positive living HEK293T Clover-PPARγ1 + mRuby2-RXRα and HEK293T Clover-PPARγ1 + mRuby2-RXRα ∆414-462 cells is depicted in (F). Flow 
cytometry-based FRET efficiencies, depicted in (G), are calculated as described in Materials and Methods. Values are means ± SD of three experiments. **P ≤ 0.01, ***P ≤ 0.001. 
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Protein-protein interactions of Clover- 
PPARγ1 – mRuby2-RXRα and Clover-PPARγ1 
– mRuby2-RXRα ∆414-462 determined by flow 
cytometry-based FRET 
Using the established experimental setup and 
the gating strategy for FRET measurements by flow 
cytometry (Figure 1F), we analyzed the 
protein-protein interactions of Clover-PPARγ1 with 
mRuby2-RXRα and with the RXRα deletion construct 
mRuby2-RXRα ∆414-462 in living HEK293T cells to 
substantiate the functionality of our flow 
cytometry-based FRET assay system. In Figure 3E, a 
representative flow cytometry-plot is shown. 
Consequently, due to the deletion of the C-terminus 
of mRuby2-RXRα ∆414-462, which is necessary for 
PPARγ1-binding, cells expressing this deletion 
construct showed reduced binding to 
Clover-PPARγ1. In this case, only 11.5% of the double 
positive (Figure 3E, right panel 1, upper right 
quadrant) HEK293T cells expressing Clover-PPARγ1 
and mRuby2-RXRα ∆414-462 showed a FRET signal 
(Figure 3E, right panel 3) whereas 72.9% of double 
positive (Figure 3E, left panel 1, upper right 
quadrant) HEK293T Clover-PPARγ1 + 
mRuby2-RXRα cells showed a FRET signal 
(Figure 3E, left panel 3). Overall, the percentage of 
FRET-positive HEK293T Clover-PPARγ1 + 
mRuby2-RXRα cells was significantly higher 
compared to HEK293T cells expressing 
Clover-PPARγ1 and mRuby2-RXRα ∆414-462. Hence, 
flow cytometry-based FRET gives a robust readout for 
the interaction of PPARγ1 with RXRα that is highly 
superior as compared to non-background corrected 
co-localization microscopy (Figures 3D vs 3F). FRET 
efficiencies (Figure 3G) reflect FACS data. 
Appropriate gating is shown in Supplementary 
Figure 4. 
Functional expression of Clover-PPARγ1 and 
N-CoR2-mRuby2 constructs protein 
The protein expression of fusion proteins, 
Clover-PPARγ1, N-CoR2 WT-mRuby2 (Figure 4A 
and 4B), N-CoR2 (∆ID1 exon)-mRuby2 (Figure 4B), 
N-CoR2 (∆ID1 CoRNR box)-mRuby2 (Figure 4B) and 
N-CoR2 (∆ID2 CoRNR box)-mRuby2 (Figure 4B), was 
determined by Western blot analysis. Clover-PPARγ1 
was detected using an anti-PPARγ1 antibody 
(Figure 4C) and an anti-GFP antibody (Figure 4D) in 
HEK293T cells stably expressing this fusion protein. 
In cells stably expressing N-CoR2-mRuby2 constructs 
alone or in combination with Clover-PPARγ1, 
N-CoR2 WT-mRuby2, N-CoR2 (∆ID1 exon)-mRuby2, 
N-CoR2 (∆ID1 CoRNR box)-mRuby2 and N-CoR2 
(∆ID2 CoRNR box)-mRuby2 could all be determined 
with an antibody against N-CoR2 (Figure 4E) and 
tRFP (Figure 4F). WT and Mock transfected HEK293T 
cells were used as negative controls for expression of 
Clover-PPARγ1 (Figure 4C and 4D) and 
N-CoR2-mRuby2 constructs (Figure 4E and 4F). As 
mentioned above, our analysis at the protein level by 
Western blot indicates that the anti-tRFP antibody 
also recognizes Clover, allowing detection of a 
specific band at the level of Clover- PPARγ1. This 
band was very prominent in HEK293T cells 
co-transduced with Clover-PPARγ1 + N-CoR2 
constructs (Figure 4F), thus, showing clearly the 
simultaneous protein expression of the two fusion 
proteins in these cells.  
Mechanistic functionality of N-CoR2-mRuby2 
constructs 
To examine whether PPARγ-dependent 
transactivation is altered when the interaction domain 
of N-CoR2 is modified, we performed a set of 
experiments using a PPRE-dependent reporter 
system. HEK293T cells expressing Clover-PPARγ1 in 
combination with N-CoR2 WT-mRuby2, N-CoR2 
(∆ID1 exon)-mRuby2, N-CoR2 (∆ID1 CoRNR 
box)-mRuby2 or N-CoR2 (∆ID2 CoRNR box)-mRuby2 
were treated for 24 h with 1 µM rosiglitazone and 
compared to DMSO control treatment. Firefly and 
control Renilla luciferase luminescence values were 
determined in each sample. The ratios of Firefly to 
Renilla luciferase luminescence were used for 
normalization. 
In Clover-PPARγ1 + N-CoR2 WT-mRuby2 cells, 
rosiglitazone showed agonistic effects and led to an 
approximately 3.5-fold PPARγ-transactivation 
(Figure 5A). Compared to Clover-PPARγ1 + N-CoR2 
(∆ID1 exon)-mRuby2 and Clover-PPARγ1 + N-CoR2 
(∆ID1 CoRNR box)-mRuby2 cells, the rosiglitazone- 
induced PPARγ-transactivation was significantly 
increased. In Clover-PPARγ1 + N-CoR2 (∆ID2 
CoRNR box)-mRuby2 cells, an approximately similar 
PPARγ-transactivation as in Clover-PPARγ1 + 
N-CoR2 WT-mRuby2 cells was observed. 
Determination of the cellular localization of 
Clover-PPARγ1 and N-CoR2-mRuby2 
constructs by fluorescence microscopy 
A detailed fluorescence microscopic assessment 
of the cellular localization of HEK293T cells 
expressing fusion proteins of Clover-PPARγ1 
(panels 3 and 5), N-CoR2 WT-mRuby2, N-CoR2 (∆ID1 
exon)-mRuby2, N-CoR2 (∆ID1 CoRNR box)-mRuby2 
or N-CoR2 (∆ID2 CoRNR box)-mRuby2 (panels 2 and 
5) is shown in Figure 5B. The overlay (panel 5) 
showed a predominantly nuclear localization of 
Clover-PPARγ1 and N-CoR2-mRuby2 constructs. In 
 Theranostics 2019, Vol. 9, Issue 19 
 
 
http://www.thno.org 
5455 
all cases, when analyzing N-CoR2 constructs, strong 
red spots in the nuclei of cells were evident (here, only 
shown for N-CoR2 WT-mRuby2). However, in 
contrast to this unambiguous observation, spots like 
those seen in cells expressing N-CoR2 constructs were 
only observed for the Clover-PPARγ protein in a 
comparable variety and intensity in cells when either 
N-CoR2 WT-mRuby2 or N-CoR2 (∆ID2 CoRNR 
box)-mRuby2 (panels 3 and 5) were expressed in 
combination. This points towards co-localization and 
possible interaction of these two proteins. In cells 
expressing Clover-PPARγ1 in combination with 
N-CoR2 (∆ID1 exon)-mRuby2 or N-CoR2 (∆ID1 
CoRNR box)-mRuby2, only a small number of weak 
spots on diffuse nuclei background were found for the 
Clover-PPARγ1 protein. 
To quantify these observations, the PCC was 
used. As shown in Figure 5C, significant differences 
in PCC values are valid in HEK293T cells expressing 
Clover-PPARγ1 in combination with the different 
N-CoR2 constructs. Interestingly, the calculated PCC 
of Clover-PPARγ1 + N-CoR2 WT-mRuby2 (0.855 ± 
0.086) was significantly higher compared to 
Clover-PPARγ1 + N-CoR2 (∆ID1 exon)-mRuby2 
(0.532 ± 0.048) or Clover-PPARγ1 + N-CoR2 (∆ID1 
CoRNR box)-mRuby2 (0.636 ± 0.048). In contrast, the 
PCC of Clover-PPARγ1 in combination with N-CoR2 
WT-mRuby2 (0.855 ± 0.086) or N-CoR2 (∆ID2 CoRNR 
box)-mRuby2 (0.846 ± 0.048) remained almost 
unchanged. In comparison to these data, the 
background PCC values of cells expressing only the 
single fusion protein N-CoR2 WT-mRuby2 ID2/ID1 
(0.326 ± 0.057) were significantly lower than the PCC 
data from simultaneously expressed protein couples 
(Supplementary Figure 5), indicating co-localization 
analyses of Clover-PPARγ1 with the single different 
N-CoR2 constructs is meaningful. To finally 
differentiate binding and/or co-localization, we used 
our flow cytometry-based-FRET assay system. 
 
 
Figure 4. Protein expression analysis of Clover-PPARγ1 and N-CoR2-mRuby2 constructs. Graphical scheme of the structure of the full-length human N-CoR2 
protein (A) and the used N-CoR2 constructs, N-CoR2 WT-mRuby2, N-CoR2 (∆ID1 exon)-mRuby2 (amplified out of HEK293T cells cDNA), N-CoR2 (∆ID1 CoRNR 
box)-mRuby2 and N-CoR2 (∆ID2 CoRNR box)-mRuby2 (B). All N-CoR2 constructs were C-terminally labeled with the red fluorophore mRuby2. Western blot analysis of total 
lysate of HEK293T cells stably expressing Clover-PPARγ1, N-CoR2 WT-mRuby2, N-CoR2 (∆ID1 exon)-mRuby2, N-CoR2 (∆ID1 CoRNR box)-mRuby2 and N-CoR2 (∆ID2 
CoRNR box)-mRuby2 alone or in combination against human PPARγ1 (C), GFP (D), human N-CoR2 (E) and tRFP (F). Images are representative of experiments which were 
performed at least three times. 
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Figure 5. Mechanistic functionality and cellular localization of Clover-PPARγ1 and N-CoR2-mRuby2 constructs. A PPARγ-dependent transactivation assay was 
used to verify the mechanistic functionality of HEK293T cells expressing Clover or Clover-PPARγ1 in combination with N-CoR2 WT-mRuby2, N-CoR2 (∆ID1 exon)-mRuby2, 
N-CoR2 (∆ID1 CoRNR box)-mRuby2 and N-CoR2 (∆ID2 CoRNR box)-mRuby2 (A). HEK293T cells expressing protein(s) as indicated were stimulated for 24 h with 1 µM 
rosiglitazone. Values from PPARγ-dependent transactivation experiments are means ± SD of four to 12 individually experiments. Each PPARγ-dependent transactivation assay 
experiment was performed in quadruple. *P ≤ 0.05. Fluorescence microscopy images of HEK293T cells expressing N-CoR2 WT-mRuby2 and Clover-PPARγ1 in combination 
with N-CoR2 WT-mRuby2, N-CoR2 (∆ID1 exon)-mRuby2, N-CoR2 (∆ID1 CoRNR box)-mRuby2 and N-CoR2 (∆ID2 CoRNR box)-mRuby2 cells are depicted (B). The 
brightfield is shown in panel 1 (1). The mRuby2-positive cells are depicted in panel 2 (2), Clover in panel 3 (3), Hoechst 33342-stained cell nuclei in panel 4 (4) and an overlay to 
estimate the localization is provided in panel 5 (5). Images are representative of experiments which were performed at least three times. The PCC was used for the correlation 
quantification of the sub-cellular co-localization of Clover-PPARγ1 expressed in combination with N-CoR2 WT-mRuby2, N-CoR2 (∆ID1 exon)-mRuby2, N-CoR2 (∆ID1 
CoRNR box)-mRuby2 and N-CoR2 (∆ID2 CoRNR box)-mRuby2 in HEK293T cells (C). R-Values are means ± SD of at least seven individual cells. ***P ≤ 0.001. 
 
Determination of protein-protein interactions 
of Clover-PPARγ1 and N-CoR2 WT-mRuby2 
by flow cytometry-based FRET 
Taking into consideration that N-CoR2 is a 
well-known PPARγ interaction partner [49], we 
investigated the effects of agonistic activation of 
PPARγ or its antagonism on this protein-protein 
interaction. For this, Clover-PPARγ1 and N-CoR2 
WT-mRuby2 were stably expressed in HEK293T cells 
and treated for 24 h either with 1 µM rosiglitazone or 
10 µM GW9662 or both added simultaneously. In 
Figure 6A, a representative flow cytometry-plot is 
shown. Transferring the previously described setup 
and gating strategy to the measurement of FRET by 
flow cytometry in living cells (Figure 1F) resulted in 
roughly the same number of FRET-positive cells 
expressing Clover-PPARγ1 and N-CoR2 WT-mRuby2 
(Figure 6B), following solvent (first dot blot, panel 3), 
rosiglitazone (second dot blot, panel 3), GW9662 
(third dot blot, panel 3) or combined rosiglitazone + 
GW9662 (last dot blot, panel 3) treatment. 
In 2016, Schaufele determined the binding 
affinity of ligands based on the determination of the 
FRET intensity via the measurement of the mean 
relative fluorescence value [13]. In relation to this 
important aspect, our FRET measurements revealed 
no differences in FRET intensity following treatment 
with an agonist or an antagonist, suggesting no 
altered affinity upon ligand binding. As shown in 
Figure 6C, flow cytometry-based FRET efficiencies 
were roughly similar after stimulation for 24 h with 
10 µM of the PPARγ antagonist, GW9662, alone or in 
combination with 1 µM of the PPARγ agonist, 
rosiglitazone, or the PPARγ agonist rosiglitazone 
alone (Figure 6C). The gating strategy used is shown 
in Supplementary Figure 6. 
Co-localization analyses suggest that specific 
N-CoR2 domains modulate PPARγ1 interaction 
(Figure 5B and C). We verified these results by flow 
cytometry-based FRET. As demonstrated previously, 
Clover-PPARγ1 and N-CoR2 WT-mRuby2 showed 
high FRET signals in the range of ~ 70%. Compared to 
N-CoR2 WT-mRuby2, the lack of ID1 exon (∆AA 
2310-2338), the ID1 CoRNR box (∆AA 2329-2337) and 
the ID2 CoRNR box (∆AA 2122-2130) significantly 
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reduced the FRET signal, suggesting that these 
domains all contribute to NCoR2 binding (Figure 6D). 
Of note, the FRET results again exactly mirror the 
results from the co-localization analyses, but with 
much higher statistical confidence and background 
corrected. As a negative control, since there was no 
ligand binding in this latter experiment, we also 
analyzed whether these mutations alter the flow 
cytometry-based FRET efficiencies (Figure 6E). The 
gating strategy used is depicted in Supplementary 
Figure 7. As expected, the mutants showed less FRET 
with PPARγ1, in line with the number of 
FRET-positive cells, indicating a reduced overall 
number of total molecules that interact. Altogether, 
this data demonstrate that our assay is sensitive and 
reliable in measuring differences in overall 
protein-protein interactions (percentage of 
FRET-positive cells), as well as binding affinity 
between proteins in the presence or absence of ligands 
(flow cytometry-based FRET efficiency).  
 
 
Figure 6. Flow cytometry-based FRET-measurements to analyze protein-protein interactions between Clover-PPARγ1 and N-CoR2-mRuby2 constructs. 
Representative primary flow cytometry-plots showing the quantity of FRET-positive living HEK293T Clover-PPARγ1 + N-CoR2 WT-mRuby2 cells are depicted (A). Images are 
representative of experiments which were performed three times. The cells were cultured for 24 h with DMSO, 1 µM of the PPARγ agonist, rosiglitazone, and 10 µM of the 
PPARγ antagonist, GW9662, alone or in combination. Panel 1 (1) represents the gating for Clover/mRuby2-double positive cells. Panel 2 (2) depicts cells positive for the first 
FRET gate of FRET 488/610nm vs. mRuby2 561/610 nm and panel 3 (3) shows cells with a FRET signal. Numbers in panels (2) and (3) represent total percentages of cells within 
the FRET gates. A comparison of the total percentages of FRET-positive living HEK293T Clover-PPARγ1 + N-CoR2 WT-mRuby2 cells is depicted in (B). The relative 
flow cytometry-based FRET efficiencies calculated as described in Materials and Methods are presented in (C). Comparison of the total percentages of FRET-positive 
living HEK293T Clover-PPARγ1 + N-CoR2 WT-mRuby2, Clover-PPARγ1 + N-CoR2 (∆ID1 exon)-mRuby2, Clover-PPARγ1 + N-CoR2 (∆ID1 CoRNR box)-mRuby2 and 
Clover-PPARγ1 + N-CoR2 (∆ID2 CoRNR box)-mRuby2 cells are depicted in (D). Flow cytometry-based efficiencies of Clover/mRuby2-double positive cells, calculated as 
described in Materials and Methods, are shown in (E). Values are means ± SD of three experiments. **P ≤ 0.01 and ***P ≤ 0.001. 
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Figure 7. Transfer of the flow cytometry-based FRET system to J774A.1 macrophages. Flow cytometry-based FRET efficiency was determined in murine J774A.1 
macrophages following transduction with (A) Clover + mRuby2 or Clover fused (63bp) mRuby2 and (B) Clover-PPARγ1 in combination with N-CoR2 WT-mRuby2 or N-CoR2 
(∆ID exon)-mRuby2. Flow cytometry-based FRET efficiencies of Clover/mRuby2-double positive cells were calculated as described in Materials and Methods. 
 
Validation of the flow cytometry-based FRET 
system in murine J774A.1 macrophages 
Based on our results obtained in HEK293T cells 
we were interested to see, whether the flow 
cytometry-based FRET system can be used in more 
difficult to transfect cells as well. Therefore, we 
performed a final set of experiments using the murine 
macrophage cell line J774.A1. As shown in 
Supplementary Figure 8, gating for 
Clover/mRuby2-positive cells expressing Clover + 
mRuby2 and Clover fused (63bp) mRuby2 was 
performed. Fluorescence medians of Clover (488/525 
nm), FRET (488/610 nm), and mRuby2 (561/610 nm) 
were used to calculate FRET efficiency, including 
medians of fluorescence negative J774A.1 cells as 
background control. Flow cytometry-based FRET 
efficiencies in J774A.1 cells (Figure 7A) were similar to 
the values in HEK293T cells (Figure 1G). Transduced 
J774A.1 cells expressing Clover-PPARγ1 and NCoR2 
WT-mRuby2 or NCoR2 (∆ID1 exon)-mRuby2 were 
analyzed in analogy to HEK293T cells for 
protein-protein interaction of PPARγ1 and NCoR2. 
Following appropriate gating (Supplementary Figure 
9), Clover/mRuby2-double-positive cells were 
analyzed for flow cytometry-based FRET. As shown 
in Figure 7B, similarly to HEK293T cells the deletion 
of ID1 exon in NCoR2 prevented interaction to 
PPARγ1, which was visible with the NCoR2 
WT-mRuby2 construct. 
Discussion 
In 2010, Banning et al. described a new 
innovative flow cytometry-based FRET assay to detect 
protein-protein interactions in living cells [8]. 
Compared to previous reports that combined flow 
cytometry and FRET [73, 74], Banning and colleagues 
designed an assay that allows quantitation and 
statistical analysis, eliminates cross talk artefacts and 
is easy to adapt and transferable to other applications 
[8]. A unique advantage of such a flow 
cytometry-based FRET assay is that the FRET 
efficiency can easily be quantified as the percentage of 
FRET-positive cells. Besides the many advantages 
offered by this assay, there are also some critical 
points that need to be taken into consideration. These 
include the fluorophores chosen, the steric orientation 
of the fluorophores, the expression and size of the 
fusion protein, the quantity of interacting proteins 
and finally, the distance between both interaction 
partners. One pivotal aspect of Banning´s flow 
cytometry-based FRET assay which could be 
improved, because it is a limiting factor, is the choice 
of the fluorophores. The FRET pair previously used, 
CFP/YFP, which are commonly used as donors and 
acceptors, respectively, have major limitations in their 
applicability. On the one hand, this is due to the 
pH-sensitivity of the YFP, which is tightly coupled to 
halide binding, and on the other, the multiple 
fluorescent states of CFP, its pH-dependence and low 
quantum yield [75, 76]. To overcome most of the 
major problems, we sought to use a new, 
systematically developed FRET pair consisting of 
green and red fluorophores. FRET pairs using GFPs as 
donors and RFPs as acceptors are less commonly 
used, but exhibit fewer of the above mentioned 
disadvantages of CFP/YFP pairs [77–81]. In the 
literature, it is reported that compared to the FRET 
pair CFP/YFP, the green/red fluorophore pairing of 
Clover/mRuby2 has an increased Förster distance 
and an improved dynamic range [14, 82, 83]. In line 
with the findings of Lam and colleagues, using the 
“gold standard” method FLIM to verify FRET, we also 
confirmed that Clover/mRuby2 (Figures 1D and E) 
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are an appropriate fluorophore pair for our 
cytometry-based FRET measurements. Our FLIM 
measurements show clearly the prolonged 
fluorescence lifetime of Clover compared to EGFP 
(Supplementary Figure 10). In addition, we were able 
to demonstrate a shift in the fluorescence lifetime of 
Clover resulting from changes in FRET activity. Such 
a shift, which is necessary for the FRET detection, 
could not be shown even for different AA linker 
lengths between EGFP and mRuby2 in our 
fluorophore fusion construct. As expected, we were 
able to easily transfer the adapted setup and gating 
strategy, using standard flow cytometry equipment, 
to measure FRET by flow cytometry in living cells 
with Clover/mRuby2. Thus, responses to these 
fluorophores either alone, in combination or fused 
were detectable as a high FRET of the positive control 
Clover fused (63bp) mRuby2 compared with the 
undetectable FRET from the negative control in 
HEK293T cells expressing Clover and mRuby2 
simultaneously as distinct proteins (Figure 1F and G 
as well as Supplementary Figure 1).  
The focus of current rational drug development 
is not only based on whether and where an active 
substance binds to cause changes in protein-protein 
interactions, but also on the affinity and the molecular 
features of the protein-protein interactions. In order to 
address these current questions, we modified and 
expanded the flow cytometry-based FRET system, 
developed by Banning and colleagues [8], with an 
additional variable. In addition to the findings in 2016 
of Banning and colleagues [8], Schaufele determined 
binding affinity based on the analysis of the FRET 
intensity via measurement of the MFI value [13]. To 
our knowledge, currently, no assay system has been 
described nor is available that combines the aspects of 
both systems. For this reason, we combined both 
assay systems for the investigation of binding 
intensity and affinity during the complex 
protein-protein interactions of PPARγ to its co-factors 
RXRα and NCoR2. This interaction plays a crucial role 
in the development of several obesity-related cancers 
and as a molecular and pharmacological target for 
autoimmune and inflammatory diseases [15–17]. 
PPARγ regulates gene expression upon 
heterodimerization with RXRα [35, 37]. Thus, RXRα is 
the most important PPARγ co-factor. The significantly 
reduced FRET observed in HEK293T Clover-PPARγ1 
+ mRuby2-RXRα ∆414-462 compared to HEK293T 
Clover-PPARγ1 + mRuby2-RXRα cells (Figures 3E, 
F, and G as well as Supplementary Figure 4) showed 
clearly that such protein-protein interactions can be 
detected using our flow cytometry-based FRET 
assay system. 
N-CoR2 is expressed ubiquitously and as an 
important PPARγ co-repressor it plays a crucial role 
in adipocyte differentiation and regulation of 
adipogenesis, insulin sensitivity, type 2 diabetes 
mellitus and PPARγ transcriptional activity [49, 50, 
84]. In recent years, a multitude of studies have 
described NHR – N-CoR2 binding and protein 
interactions [66, 67, 85, 86]. Current reports show that 
NHRs generally bind more effectively to N-CoR2 in 
the absence of ligands or in the presence of 
antagonists [49, 54]. Thus, in addition to establishing 
the combined flow cytometry-based FRET system, we 
characterized the influence of specific PPARγ ligands 
on PPARγ1 – N-CoR2 binding and protein-protein 
interactions (Figure 6A). Interestingly, we found that 
in the absence (DMSO) or presence of the PPARγ 
antagonist, GW9662, no change in FRET-positive cells, 
in terms of total number of PPARγ1 – N-CoR2 binding 
and protein interactions, was observed (Figure 6B). 
The administration of the PPARγ agonist, 
rosiglitazone, also did not significantly alter the 
number of FRET-positive cells, indicating now change 
in PPARγ1 – N-CoR2 binding and protein 
interactions. This observation also confirms data in 
the current literature.  
In the last few years, a variety of studies have 
shown that agonist binding to PPARγ results in a 
conformational change in the PPARγ receptor, 
leading to destabilization of co-repressor interactions 
and the loss of N-CoR2 binding and subsequent 
recruitment of co-activators [54, 55, 84]. We propose 
that this explains our current findings. That the 
binding of the PPARγ agonist, rosiglitazone [54, 55, 
84, 87] to the PPARγ ligand binding domain (LBD) 
results in a PPARγ conformational change, needs to 
be verified in further experiments. The consequence 
of this change and the loss of N-CoR2 binding was 
experimentally demonstrated, in our case, by a 
reduced number of FRET-positive cells. The binding 
of the PPARγ antagonist, GW9662 prevents this 
conformational change, stabilizes the protein 
interaction and thus maintains PPARγ1 – N-CoR2 
binding and protein interactions, as reflected by a 
high number of FRET-positive cells. In addition, to 
verify the affinity of the PPARγ1 – N-CoR2 protein 
interactions and thereby, the effects of the PPARγ 
agonist, rosiglitazone, and antagonists, GW9662, in 
comparison to the absence of a ligand (DMSO), we 
introduced a new tool, determining the binding 
affinity based on the determination of the FRET 
intensity via the measurement of the MFI value [13]. 
This modification revealed that neither antagonist nor 
agonist treatment altered PPARγ1 – N-CoR2 binding 
(Figure 6C and Supplementary Figure 6). 
Importantly, flow cytometry-based FRET efficiencies 
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have to be calculated from raw flow cytometric data 
[10–12]. 
Physiologically relevant variations in the 
interactions between these two proteins exist with 
respect to the expressed protein isoforms. In the 
literature it has been reported that the N-CoR2 – NHR 
interaction, as well as its functional transcriptional 
co-repressor activity, is controlled by its protein 
structure. Crucial for these functions are the two 
C-terminal IDs (ID1 and ID2) of N-CoR2, that contain 
CoRNR box (NHR box) motifs which mediate the 
interaction between co-repressors and NHRs [13, 52, 
54, 55, 84, 88]. Furthermore, it has been reported that 
alternative splicing of single IDs or splicing among 
them has crucial consequences for their functions as 
an interaction partner of PPARγ [53–58]. Because of 
the surprising result of the N-CoR2 amplification of 
HEK293T cells, in which we amplified the N-CoR2 
(∆ID1 exon) variant, we further developed different 
N-CoR2 constructs to study the influence of selected 
AA deletions on PPARγ – N-CoR2 protein 
interactions.  
With deletions in the N-CoR2 interaction 
sequence, we detected significant differences in 
FRET-positive HEK293T cells. Compared to N-CoR2 
WT-mRuby2, the lack of ID1 exon, CoRNR box ID1 
(G…LEAIIRKALM), and CoRNR box ID2 
(G…LAQHISEVI…K), which are essential for nuclear 
receptor binding to N-CoR2, significantly reduced the 
FRET signal. From these data, we assume that both 
interacting domains are important for the formation 
of a PPARγ/N-CoR2 complex. Furthermore, we 
observed that the deletion of only the ID1 motif itself 
(ID AA) decreased the binding capacity of the protein 
couple but not as efficiently as a complete lack of the 
ID1-containing exon of N-CoR2. Thus, it appears that 
some AA in the remaining ID1 exon are also 
important for stabilizing the protein-protein 
interaction or that the deletion of the exon mediates 
drastic changes in the quaternary structure of 
N-CoR2, which hampers the process of successful 
binding. As reported in the literature, our data 
indicate that the binding and the associated PPARγ – 
N-CoR2 protein interactions are strongly dependent 
on the N-CoR2 AA sequence, in which the interaction 
between this protein couples is mainly dictated by the 
ID1 CoRNR box motif. This aspect is also supported 
by the fluorescent microscopy analysis, which clearly 
showed a strong co-localization correlation only 
between PPARγ and the ID1 AA containing N-CoR2. 
However, where co-localization binding occurs, it 
appears to be with the same affinity as that during the 
flow cytometry-based FRET protein-protein 
interaction measurements, independently of the 
N-CoR2 AA modification. 
Our cytometry-based FRET assay data, 
especially the outstanding role of ID1 observed 
during the interaction, were also supported and 
confirmed by studies of the mechanistic functionality 
of N-CoR2 WT-mRuby2 and N-CoR2 (∆ID1 
exon)-mRuby2, using a PPARγ-dependent 
transactivation assay. Administration of the PPARγ 
agonist, rosiglitazone, led to an explicit PPARγ 
transactivation, whereas, in all cases, the 
administration of the PPARγ antagonist, GW9662, 
prevented the PPARγ transactivation, independently 
of the N-CoR2 AA sequence modification. The 
analyses were done in HEK293T cells and therefore, 
control cells expressing only Clover-PPARγ without 
N-CoR2-mRuby2 inherit only the endogenous 
N-CoR2 with the missing ID1 exon, which results in 
nearly the same transactivation levels as in cells 
overexpressing N-CoR2 (ΔID1 exon)-mRuby2. In spite 
of the repressor nature of N-CoR2, we failed to detect 
a repression of transactivation in comparison to the 
control PPARγ alone. A possible explanation for this 
observation could be that the N-CoR2 constructs we 
utilized lack most of their regular N-Terminus (ΔRD1, 
SANT, ΔRD2), so that their AA sequence starts with 
RD3. As a result, N-CoR2 cannot interact to a full 
extent with other proteins of the normal repressor 
complex, like SIN3, the G-protein pathway 
suppressor (GPS2), transducin (beta)-like 1X-linked 
(TBL1)/transducin (beta)-like 1X-linked receptor 1 
(TBLR1) and histone deacetylase 3 (HDAC3) and 
therefore, the repression of transcription is lost [89, 
90]. Nevertheless, with this assay, we could show that 
the ID1 domain of N-CoR2 enhances the functional 
outcome of the PPARγ – N-CoR2 interaction, by 
leading to a strong transactivation rate in 
rosiglitazone treated cells. This conclusion is well 
supported by the significant FRET reduction of 
Clover-PPARγ1 + N-CoR2 (∆ID1 exon)-mRuby2 and 
also by the absent co-localization of this protein 
couple in living HEK293T cells. Further detailed 
studies are needed to elucidate mechanistic details. 
We finally proved that our flow cytometry-based 
FRET system can also be used in cells which can 
barely be transfected/transduced compared to 
HEK293T cells. Thus, in murine J774A.1 
macrophages, the flow cytometry-based FRET assay 
revealed similar results compared to HEK293T cells, 
although the number of double positive cells was 
significantly lower. These data support the notion that 
our system is also suitable to determine 
protein-protein interactions in cells which are more 
difficult to handle.  
NHR such as PPARγ1 are directly involved in 
many disease pathways. Most of them have been the 
subject of screening assays to detect protein-protein 
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interactions and to identify compounds for the 
characterization of co-factor recruitment and selective 
modulators. For practical reasons, such efforts at drug 
development have mainly relied on cell-free receptor 
homo- or heterodimers on DNA [91]. Moreover, the 
major readout for compound screening assays has 
been co-regulator recruitment. These studies have 
been guided by the assumption that different NHR 
ligands can impart their gene-selective actions strictly 
through their differential impact on co-regulator 
affinities. Given that co-regulator availability differs 
in cell types, the altered affinities are thought to give 
rise to selective modulator properties in these ligands.  
Conclusions 
In this report, we clearly show that our 
innovative, systematically improved, cytometry- 
based FRET assay provides detailed, reliable, 
reproducible data and allows the molecular 
identification and characterization of direct 
protein-protein interactions of the human nuclear 
factor PPARγ1 with its co-factors in living cells as well 
as permitting identification of novel protein 
interaction partners. The setting opens the possibility 
of transfer to other NHR to identify their binding 
characteristics to co-activators and co-repressors also 
in an HTS approach. Thus, this assay is expected to 
contribute to the identification of a variety of novel 
therapeutic targets for treatment of human diseases.  
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